These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 2300790)

  • 1. Increased amounts of C4-containing immune complexes and inefficient activation of C3 and the terminal complement pathway in a patient with homozygous C2 deficiency and systemic lupus erythematosus.
    Garred P; Mollnes TE; Thorsteinsson L; Erlendsson K; Steinsson K
    Scand J Immunol; 1990 Jan; 31(1):59-64. PubMed ID: 2300790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of immune complex-mediated complement activation by autoantibodies (F-42) isolated from sera of patients with systemic lupus erythematosus.
    Daha MR; Hazevoet HM; Vanes LA
    Clin Exp Immunol; 1983 Sep; 53(3):541-6. PubMed ID: 6604604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reconstitution of the alternative pathway of complement by plasma infusions given to a patient with an SLE-like syndrome associated with a hereditary C3 dysfunction.
    Nilsson B; Nilsson UR; Karlsson-Parra A; Sjölin-Forsberg G; Hällgren R
    Ann Rheum Dis; 1994 Oct; 53(10):691-4. PubMed ID: 7979584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factor B activation products in patients with systemic lupus erythematosus. A marker of severe disease activity.
    Kerr LD; Adelsberg BR; Schulman P; Spiera H
    Arthritis Rheum; 1989 Nov; 32(11):1406-13. PubMed ID: 2818657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Components of the classical complement pathway in systemic lupus erythematosus].
    Maillet F; Goetz J; Hauptmann G; Clauvel JP; Mery JP; Kahn MF; Kazatchkine M
    Presse Med; 1987 Mar; 16(8):378-82. PubMed ID: 2950498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of immune precipitation by purified classical pathway complement components.
    Naama JK; Hamilton AO; Yeung-Laiwah AC; Whaley K
    Clin Exp Immunol; 1984 Nov; 58(2):486-92. PubMed ID: 6333948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Classical pathway deficiencies - A short analytical review.
    Truedsson L
    Mol Immunol; 2015 Nov; 68(1):14-9. PubMed ID: 26038300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relative importance of C4 binding protein in the modulation of the classical pathway C3 convertase in patients with systemic lupus erythematosus.
    Daha MR; Hazevoet HM; Hermans J; van Es LA; Cats A
    Clin Exp Immunol; 1983 Oct; 54(1):248-52. PubMed ID: 6604610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Lupus and protein deficiencies of the classical complement pathway].
    Weiss L; Maillet F; Kazatchkine M
    Rev Prat; 1990 Sep; 40(21):1937-40. PubMed ID: 2237185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mannan-binding lectin may facilitate the clearance of circulating immune complexes--implications from a study on C2-deficient individuals.
    Saevarsdottir S; Steinsson K; Ludviksson BR; Grondal G; Valdimarsson H
    Clin Exp Immunol; 2007 May; 148(2):248-53. PubMed ID: 17335556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utilization of complement testing in clinical medicine.
    Abdul-Aziz K; Faizal AA
    Saudi Med J; 2006 Nov; 27(11):1775-7. PubMed ID: 17106567
    [No Abstract]   [Full Text] [Related]  

  • 12. C3, C4, and the terminal complement complex differ from C1q by binding predominantly to the antigenic part of solid phase immune complexes.
    Garred P; Michaelsen TE; Aase A; Mollnes TE
    J Immunol; 1990 Jan; 144(1):198-203. PubMed ID: 2295791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential studies of complement activation in systemic lupus erythematosus.
    Sturfelt G; Johnson U; Sjöholm AG
    Scand J Rheumatol; 1985; 14(2):184-96. PubMed ID: 4001891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between the component and regulatory proteins of the classical pathway C3 convertase.
    Welch TR; Forristal J; Beischel L
    J Lab Clin Med; 1986 Jun; 107(6):529-33. PubMed ID: 3635565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C3 metabolism in a patient with deficiency of the second component of complement (C2) and discoid lupus erythematosus.
    Wild JH; Zvaifler NJ; Müller-Eberhard HJ; Wilson CB
    Clin Exp Immunol; 1976 May; 24(2):238-48. PubMed ID: 1084239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of the alternative complement pathway accompanies disease flares in systemic lupus erythematosus during pregnancy.
    Buyon JP; Tamerius J; Ordorica S; Young B; Abramson SB
    Arthritis Rheum; 1992 Jan; 35(1):55-61. PubMed ID: 1731815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypercatabolism of C3 and C4 in active and inactive systemic lupus erythematosus.
    Charlesworth JA; Peake PW; Golding J; Mackie JD; Pussell BA; Timmermans V; Wakefield D
    Ann Rheum Dis; 1989 Feb; 48(2):153-9. PubMed ID: 2784659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The complement system].
    Lambert PH
    Schweiz Med Wochenschr; 1975 Sep; 105(37):1180-4. PubMed ID: 1215899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complement activating cryoglobulins in the nephritis of systemic lupus erythematosus.
    Adu D; Williams DG
    Clin Exp Immunol; 1984 Mar; 55(3):495-501. PubMed ID: 6705265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of complement components C1q and C4 bound to circulating immune complexes in juvenile idiopathic arthritis: support for classical complement pathway activation.
    Gilliam BE; Reed MR; Chauhan AK; Dehlendorf AB; Moore TL
    Clin Exp Rheumatol; 2011; 29(6):1049-56. PubMed ID: 22153664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.